Kestra Medical Technologies (NASDAQ:KMTS) Trading Up 10.2% – Here’s Why

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)’s stock price rose 10.2% on Thursday . The company traded as high as $22.82 and last traded at $22.7940. Approximately 4,992 shares were traded during trading, a decline of 98% from the average session volume of 316,654 shares. The stock had previously closed at $20.69.

Analyst Ratings Changes

Several research analysts have issued reports on KMTS shares. Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 15th. Wall Street Zen upgraded shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research report on Saturday. BTIG Research reissued a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research note on Tuesday, April 7th. Finally, The Goldman Sachs Group dropped their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $27.40.

Kestra Medical Technologies Stock Up 17.1%

The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -6.67 and a beta of 0.83. The firm has a 50 day moving average of $21.05 and a 200 day moving average of $22.78. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15.

Insider Activity

In other news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the completion of the sale, the insider owned 395,467 shares of the company’s stock, valued at $8,229,668.27. This trade represents a 3.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders sold 45,000 shares of company stock worth $927,150. 3.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of KMTS. Farther Finance Advisors LLC bought a new stake in Kestra Medical Technologies in the fourth quarter valued at $31,000. Russell Investments Group Ltd. boosted its position in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at about $72,000. Finally, Brown Brothers Harriman & Co. increased its position in Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.